In our design, we selected affibody ZHER2:342 as the target ligand, whose N-terminal is fused with Fc domain, with a recognition site for the uPA enzyme that is highly active at the tumor site inserted between them, and the sortase A-mediated enzymatic reaction as the site-specifically coupling strategy to construct the target ADC molecules. The gene discussed is PLAU; the disease is neoplasm.